Soursop tea in people with relapsed or hard-to-treat leukemia or myeloma
Tests soursop leaf tea in adults with relapsed acute myeloid leukemia or multiple myeloma.
Plain-language title generated from the registry record
Registry title: A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)
Key facts
- Where
- Camden, United StatesSee the site
- Phase
- Early phase 1
Where in United States
- MDA at Cooper University Health CareCamden, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Roger Strair
- Trial code
- NCT07771803
- Record updated
- 18 August 2026
- Original description
Purpose/Specific AimsRead full original descriptionShow less
A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)
Purpose/Specific Aims
The study will determine if there is a reduction in malignant cell burden when patients with relapsed and/or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) consume tea made from the dried leaves of Annona muricata (Soursop).
The study goal is to determine the safety and anti-neoplastic efficacy of Annona muricata tea when taken in escalating frequency over a period of 21 days by patients with relapsed/refractory AML or MM for whom there are no standard therapeutic options.
Inclusion: Patients with relapsed or refractory AML or MM not on any anti-neoplastic therapy who have exhausted all therapies and have no available therapy; For AML: Quantifiable leukemia cells in blood (patients without circulating AML blasts may participate if they agree to baseline and post-treatment bone marrow testing); For MM: Quantifiable M component (SPEP) or serum free light chain abnormality (ratio greater than 10); ECOG PS 0,1, or 2; ALT, AST less than 3 times ULN; Bilirubin (total) < 2.5 mg/dL; Renal function - estimated GFR > 40 ml/min; No uncontrolled/active infections; Negative pregnancy test if of childbearing potential; No chronic neurologic disorders (peripheral neuropathy > grade 2; Parkinson's disease; Alzheimer's disease; other neurologic diseases will be discussed with the PI).
Exclusion: Inability to understand the study procedures; Inability to understand the consent form --Pregnancy, breastfeeding, or inability or unwillingness to use effective contraception.